The purpose of this randomized, double-blind study was to examine the effect of GaAs laser therapy for tendinitis and myofascial pain in a sample from the general population of Åkersberga in the northern part of Greater Stockholm. 176 patients (of an original group of 200) completed the scheduled course of treatment. The patients were assigned randomly to either a laser group (92 patients, of whom 74 had tendinitis, completed the study) or a placebo group (84 patients, of whom 68 had tendinitis, completed the study). All 176 patients received six treatments during a period of 3-4 weeks. Their pain was estimated objectively using a pain threshold meter, and subjectively with a visual analogue scale before, at the end of, and four weeks after the end of treatment. Laser therapy had a significant, positive effect compared with placebo measured from the first assessment to the third assessment, four weeks after the end of treatment. Laser treatment was most effective on acute tendinitis.
Introduction
It is important to find effective treatment methods for pain conditions in muscles and joints, as illnesses in the musculoskeletal system constitute the major contribution to the total number of sick-leave days in Sweden, due to the rather long periods of sick-leave associated with these conditions. These patients usually turn to primary health care, where LLLT may be a useful treatment. Physiotherapists use many different forms of treatment but few have undergone critical evaluation. Low level laser therapy (LLLT) has not yet been fully adopted as a treatment method in Sweden. The purpose of this randomized, double-blind study was to examine the effect of gallium arsenide (GaAs) diode laser treatment of tendinitis and myofascial pains. In the extensive literature on LLLT there are many double-blind studies, but to the authors can identify only a few where GaAs lasers were used on similar diagnoses (1) (2) (3) (4) (5) (6) and conclusions as to the efficacy of laser therapy have not always been in accord, probably owing to the difficulty in making optimal choices of the treatment parameters (dose, laser wavelength, pulse frequency, output power, treatment technique and treatment interval).
Background
Laser light of certain wavelengths possesses the capability of penetrating into living tissue. As early as 1968 it had been reported that laser light influences living tissue. (7) These effects were named 'biostimulative' effects of laser light by the late Endré Mester. The most common name today is low level laser therapy, or LLLT. Much research has been done on the effects of LLLT with different laser types. It has been shown, not only that different laser types produce different biological effects, but also that different pulse frequencies of pulsed lasers, bring about different biological responses. (8) LLLT with gallium arsenide (GaAs), helium neon (HeNe) and gallium aluminium arsenide (GaAlAs) lasers is based on the photobiological effects produced by laser light absorbed in the target tissue. It should be noted that these effects are not attributed to heat energy. The heat generated during LLLT is nonexistent or negligible. The photobiological effects in turn trigger different biochemical reactions. (9) (10) (11) (12) (13) (14) There are two main fields of application in LLLT for medical lasers: they are used to treat conditions related to skin and mucous membranes (with the HeNe laser tending to be the laser of choice) and they are used on problems of muscles, tendons and joints, for which the GaAlAs and GaAs lasers are regarded as the most suitable type. The light from GaAs lasers (emitting a pulsed, invisible near infrared light at a wavelength of 904 nm), with short but very strong light pulses, can theoretically deliver a more clinically useful dose of photons deeper into the tissue than the light from the two other continuous wave laser types mentioned, and is therefore possible better suited for treating deeper probl ems.
The most important treatment parameter is the dose D, defined as D=Pt/A, measured in J/cm2, also called the energy density, where P = the average output power in watts, t = the exposure time in seconds and A = the treated area in square centimetres. Dose and treatment interval may only be indicated schematically. Different laser wavelengths require that different doses be administered, the same applying to the different conditions to be treated. Patients are not equally sensitive to laser treatment. Some patients are very susceptible, a smaller number of patients seem to be completely unsusceptible. The dose and treatment interval also differ depending on whether the condition is acute or chronic.
Please observe that the dose refers to the energy that really enters the tissue, that is to say the incident energy density. If the therapist does not bring the laser probe into skin contact but treats his or her patients with the probe held at a distance from the skin surface, a good deal of the light energy can be lost through reflection from the surface of the target tissue. It has been suggested that the effect of LLLT is at least partly cumulative and this is one of the reasons why treatment should be carried out with adequate intervals, so as to avoid entering the biosuppressive dose range. Acute conditions normally require fewer treatments, therefore they can be scheduled reasonably close to one another. Chronic conditions are preferably treated with longer intervals. Side effects are rarely seen after LLLT. The most common side effect is local pain lasting for a day or so, the day after the first treatment. This is normal, and if the patient is forewarned about this possibility, and that subsequent LLLT sessions will quickly control the pain, this does not pose a problem.
Treatment Parameters
The laser used in this study was a GaAs laser with a wavelength of 904 nm. The selected pulse frequency was 4,000 Hz. Each pulse has an amplitude of about 10 W and a duration of 180 ns. The laser probe thus had an average output power of 8 mW.
The treatment technique used was to give actual laser therapy or placebo only on certain, separate points: on trigger points, over muscle origins and over insertions. The dose given to those in the laser group on each treatment point was between 0.5 and 1.0 J/cm 2 . The higher doses were used for more deeply seated anatomical structures and the lower doses for more superficially located structures. Six treatments were given during a period of 3 -4 weeks. The two physiotherapists responsible for diagnosis and interviews decided which points to treat and the dose/treatment time to be used.
Patients and Trial Method
Two externally identical probes (except for a code; one probe was marked A and the other one B) were used for treatment. In the study, only one of the probes emitted laser radiation during operation. The other one was a dummy, but otherwise behaved in exactly the same way as the real laser. As the radiation from a GaAs laser is invisible and does not produce any perceptible heat, it was not possible for patients or therapists to find out which probe was the active laser and which was the dummy. The significance of the codes was unknown to the therapists and patients. The codes were known only to a technician who had no contact with the therapists or patients. The codes were changed three times during the 18-month period of the study. Of course, there was no change of code or probe during the treatment of any one patient. The technician also made sure that the laser probe functioned properly and supplied the right output power. Five therapists performed the treatments of the 176 patients.
The measurement of patients' pain is hardly ever objective, but we have, like Haker and Lundeberg (21) measured the pain threshold using a Pain Threshold Meter (PTM) which is regarded to be a reasonably objective method. (15, 16) The PTM consists of a rubber disk 1 cm in diameter connected by a rod to a spring-loaded indicator needle on a calibrated pressure gauge, marked in kg or lbs. In the present study we used the kg readings. As the rubber disk is 1 cm in diameter, the pressure applied is expressed in kg/cm 2 . When the maximum pressure to cause pain is achieved, the probe is removed from the skin but the needle remains at the setting until it is returned to zero by pressing the zeroing knob.
The PTM is used for location of tender spots, trigger points and so on, and quantification of their sensitivity in order to document their existence to the patient or for medical and legal purposes. Trigger points are small exquisitely sensitive areas of soft tissue, which sometimes shoot pain into a remote "reference pain zone." Trigger points are present in myofibrositis, fibromyalgia, myofascial pain syndrome, nerve irritation, endocrine and metabolic diseases, amongst other conditions. If measured before and immediately after treatment such as injection, physical therapy, or manipulation, the PTM will show the efficacy of the intervention or the opposite. Long term follow-up usually at two week intervals will demonstrate patient's progress or lack of changes. Activity of inflammatory processes including arthritis and fibrositis can be assessed easily by the PTM.
The Ethical Committee of the Karolinska Institute, Stockholm, gave its approval for the execution of the study. Over a period of 18 months (1989 -1991) , 200 patients were examined and were invited to participate in the study. One hundred and seventy six patients completed the scheduled six sessions of treatment and the follow-up examination four weeks after the end of the treatment. The drop-out was thus 12%. The patients' ages varied between 18 and 78 years. The median age was 39 years and 75% of the patients were women and 25% were men, The patients were referred to the department of Physiotherapy, Health Care Centre in Åkersberga by their physician.
The patients were assigned randomly to the two groups, consecutively, and every second patient was assigned to the laser group (92 patients completed the study, of whom 74 had tendinitis) and the placebo group (84 patients completed the study, of whom 68 had tendinitis) respectively. All 176 patients received six treatments during a period of 3-4 weeks. Their pain was assessed objectively (PTM) and subjectively (visual analogue scale, VAS) before, at the end of, and four weeks after the end of treatment.
Of the original group of 200 patients (of whom 100 belonged to the laser group and 100 to the placebo group), 24 dropped out: 8 from the laser group and 16 from the placebo group.
Two physiotherapists, considered to be carrying out their work in a very similar manner, diagnosed the patients and interviewed them before the treatment started regarding the duration of their condition. and the type(s) of previous treatment received (Tables 1, 2 and 3). Patients were informed that they would be treated with either laser or placebo, both free of charge. The patients assigned to the placebo group would receive laser treatment after the follow-cup examination four weeks after the end of treatment, if they still wanted to. These laser treatments were given at another centre.
Exclusion criteria:
Pregnancy: Epilepsy: Goitre: Hyperthyroidism: Untreated high blood pressure: Untreated cardiac decompensation: Tendency to develop thromboses: Patient wears a cardiac pacemaker.
Inclusion criteria:
Age above 18 years of age: Voluntary consent to inclusion in the study: Diagnosis of tendinitis or myofascial pain.
The diagnosis tendinitis was given if pain referred to a tendon, resulting from at least two of the following three tests: (1) passive stretching; (2) resistance to static muscle contraction; and (3) palpation. It may be more adequate to use the term tendalgia as in many cases it was not a true inflammatory condition in a medical sense. However, we have used the term tendinitis throughout this report. The diagnosis of myofascial pain was given if the pain provoked by palpation of trigger points could be assigned to specific muscles or muscle groups causing the symptoms. (17) Patients were not allowed to have any form of physical treatment other than laser or placebo during the period of treatment and follow-up of the study. Intake of NSAIDs during the period of treatment and follow-up was not allowed. Cortisone injections were given neither during a one-month period prior to the start of treatment nor during the period of treatment and follow-up. was allowed. Patients were instructed to continue their normal activities but to take it easy after the treatment sessions and to avoid movements causing pain. Proper postures for work and rest were discussed.
Methods of assessment and statistical evaluation
The assessments were carried out on three different occasions: before, at the end of and 4 weeks after the end of treatment (Table 4 ). The PTM-instrument was held perpendicular to the skin and was pressed against treatment points with gradually increasing force until the patient sensed pain. The measured values (in kg) of the three most sensitive points of each patient were added. together. The same three points of every patient were measured on all three occasions. As a baseline guide, a person with healthy, normal tissues starts to sense pain when the pressure of the instrument against a point of the skin above a muscle or tendon, is usually between 3 and 6 kg, i.e. corresponding to a value of 9 -18 kg when the values from the three points are added. together. The subjective estimation was based on the interview questions presented in Tables 5 and 6 and on pain estimations with a Visual Analogue Scale (VAS). VAS estimations were performed on three separate occasions: before, at the end of and 4 weeks after the end of treatment (Table 4 ). The patients estimated the intensity of their pain (at that moment resting) on a scale from zero to 10. (No pain was scored as zero).
The collected information was processed by computer. A Student's t-test was used for the statistical evaluation of the data. Level of significance was minimum value of p < 05.
Results
The statistical evaluation of the collected data generally showed that laser had a significant, positive effect compared with placebo measured from the first assessment to the third assessment and four weeks after the end of treatment both in the evaluation of the objective (PTM) assessments as well as in the evaluation of the subjective VAS scored (Table 4) .
Fifty patients were taking some sort of analgesic. At the follow-up examination four weeks after the end of treatment these patients were asked if their consumption of analgesics had decreased during the period of treatment and follow-up (compared with their consumption before starting the treatment) ( Table 7) .
Discussion
Regarding the treatment parameters, our choice of values was based on the opinions and recommendations of different users, manufacturers or distributors of laser instruments at the time the study was planned, as well as on the capacity of the laser instrument at our disposal. Although the results of this study are quite clear as regards the effects of LLLT, it is likely that other combinations of parameters (e.g. a prolonged series of treatments) would have produced even better results.
The treatment technique involving pressing or rubbing of the tip of the probe against the treatment points could have a possible influence on how pain is experienced by patients. The treatment technique may
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M LÖGDBERG-ANDERSSON ET AL. have produced some effect on the values of pain of the placebo group as well. To avoid such a possible influence, a treatment technique where the probe is not brought in contact with the skin could be used. However, the technique where the probe is pressed against the skin is preferable since it permits the laser radiation to penetrate deeper into the tissue and avoids loss of laser radiation through reflection from the skin surface.
Group Treatment Type(s)
The therapists at the Health Care Centre at Åkersberga, who have been using LLLT since 1987, believe laser to have its strongest effect on acute cases of tendinitis. In view of the scepticism often expressed by, for example, physicians toward LLLT, it would have been preferable to single out patients with a purer diagnosis (e.g. patients with acute supraspinatus tendinitis) to participate in the study, in order to be able to demonstrate an even clearer effect of laser treatment than this study could do. This was indeed our intention, but there were some problems associated with such an approach: many acutely ill patients declined to participate in the study because of the possibility of being left without effective treatment for another 7 -8 weeks, coupled with the prospect of having to be put on the sick list because of their pains. The result was that a large part of the 176 TabIe 5: "How would you rate the effect of the treatment you received in the course of this study compared with the effect of the treatment you received prior to the study?" § participants in the study were patients who had had their pain for more than 6 months (Tables 2 and 4 ), i.e. patients with chronic rather than acute or even subacute pain.
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The objective estimations of pain in all 176 patients in general showed that the average pain threshold values in the placebo group increased in the period from the start to the end of treatment and subsequently decreased in the period from the end of treatment to the follow-up examination. The laser group generally showed a longer-lasting effect of treatment than the placebo group and even demonstrating an increase in their pain threshold averages in the period from the end of treatment to the follow-up examination, except for those patients with myofascial pain (n=34).
Conclusions
The study shows that low level GaAs laser therapy has a significant, positive effect on tendinitis and myofascial pain compared with placebo treatment. Laser therapy had the most significant effect on acute tendinitis. In order to optimize the choices of treatment parameters, further studies are needed. 
